GuruFocus DCF Values BDX at $157 vs $187 Price, Reinforcing Wait Stance

What happened

GuruFocus published a DCF analysis valuing BDX at $157 per share versus a market price near $187, implying roughly 16% downside from the September 2026 reference point. The estimate sits below the $180 base-case implied value in our internal scenario work but above the $145 bear case, reflecting a tighter set of assumptions around growth and margins than current market pricing. This valuation gap is consistent with BDX's elevated multiples (P/E of 53x and EV/EBITDA of 13x) and the unresolved tariff, BioPharma Systems growth, and remediation overhangs flagged in the latest 10-Q. The news does not introduce new fundamental information; it is a third-party valuation exercise that likely assumes lower terminal growth or higher discount rates than the market is currently applying. Taken at face value, the DCF supports our view that the stock offers limited margin of safety at current levels and that investors should prefer an entry closer to $160 or wait for concrete operating proof points.

Implication

The GuruFocus DCF provides a quantitative anchor that reinforces our existing caution: at $187, BDX trades above our base-case fair value and leaves little room for execution missteps. Investors already holding the stock should not panic, as the company's durable consumables and $2 billion in minimum-purchase obligations provide some downside protection, but new money should be patient. The next two quarterly reports are critical: if BioPharma Systems posts positive FX-neutral growth and tariff mitigation is quantified, fair value could rise toward the bull case, but if not, the $157 target may prove prescient. We maintain our attractive entry zone around $160 and would trim positions above $195, consistent with the DeepValue framework. Use any rally toward $190-195 to reduce exposure and wait for either a better price or evidence that tariffs and quality issues are resolving.

Thesis delta

No change to the overall WAIT rating. The GuruFocus DCF adds a third-party valuation estimate of $157, which is below our base-case $180 and closer to our bear case, but it does not alter the fundamental drivers we monitor. The thesis remains that BDX is a quality franchise temporarily trading above intrinsic value, best bought on weakness near $160 or after proof that BioPharma Systems and tariff mitigation are delivering.